Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425722 | 0.96 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2434874 | 0.80 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3328991 | 0.80 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL27965943 | 0.79 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8784001 | 0.78 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9013821 | 0.78 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8785032 | 0.78 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8030506 | 0.77 | CA1 (0.43) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4599958 | 0.76 | CYP19A1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7713128 | 0.76 | CA1 (0.46) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210071181-A1 | PHARMACEUTICAL COMPOSITION | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2021-03-11 | — | — | US | disclosed |
| EP-3502255-A1 | PHARMACEUTICAL COMPOSITION | Roche Innovation Center Copenhagen A/S (DK) | 2019-06-26 | — | — | EP | disclosed |
| US-20190071672-A1 | Pharmaceutical Composition | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-03-07 | — | — | US | disclosed |
| EP-3431602-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES | Roche Innovation Center Copenhagen A/S (DK) | 2019-01-23 | — | — | EP | disclosed |
| EP-2666859-B1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2019-01-02 | — | — | EP | disclosed |
| US-20180195062-A1 | Pharmaceutical Composition | SANTARIS PHARMA A/S (DK) | 2018-07-12 | — | — | US | disclosed |
| EP-2264172-B1 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA EXPRESSION | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2017-09-27 | — | — | EP | disclosed |
| US-9738894-B2 | Short interfering RNA (siRNA) analogues | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-08-22 | — | — | US | disclosed |
| US-20170009237-A1 | Short Interfering RNA (siRNA) Analogues | SANTARIS PHARMA A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| EP-2141234-B1 | Short Interfering RNA (siRNA) Analogues | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2016-04-27 | — | — | EP | disclosed |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | ENZON PHARMACEUTICALS, INC | 2005-01-20 | — | — | US | disclosed |
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | SANTARIS PHARMA A/S | 2004-12-09 | — | — | US | disclosed |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | SANTARIS PHARMA A/S | 2004-12-02 | — | — | US | disclosed |
| WO-2004083430-A2 | SHORT INTERFERING RNA (siRNA) ANALOGUES | SANTARIS PHARMA A/S (DK) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004069992-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069991-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069990-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2004-05-20 | — | — | US | disclosed |
| WO-2003085110-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA EXPRESSION | SANTARIS PHARMA A/S (DK) | 2003-10-16 | — | — | WO | disclosed |
| EP-0753525-A1 | CYCLIC NUCLEOTIDE DERIVATIVE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | HRAS, KRAS, NRAS | CA1 1247/4885CA2 3981/4885CA7 2991/4885 |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | TXN, TXN2, TXNRD3 | CA1 1861/4885CA2 4209/4885CA7 4328/4885 |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | HIF1AN, HIF1A, HYOU1 | CA1 1611/4885CA2 1862/4885CA7 2875/4885 |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | BIRC5, XIAP, BIRC3 | CA1 1782/4885CA2 4192/4885CA7 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.